-
公开(公告)号：US5487739A
公开(公告)日：1996-01-30
申请号：US459815
申请日：1995-06-02
申请人： Patrick Aebischer , Moses Goddard , John G. Moldauer , Paul J. Mulhauser , Anne M. Rathbun , Paul R. Sanberg , Alfred V. Vasconcellos , Nicholas F. Warner
发明人： Patrick Aebischer , Moses Goddard , John G. Moldauer , Paul J. Mulhauser , Anne M. Rathbun , Paul R. Sanberg , Alfred V. Vasconcellos , Nicholas F. Warner
IPC分类号： A61F2/02 , A61K9/00 , A61K9/50 , A61K35/12 , A61K35/55 , A61M31/00 , A61M39/02 , B01J13/02 , C12N5/00 , C12N5/071 , C12N5/0793 , C12N11/04 , A61K9/22
CPC分类号： A61K9/0092 , A61F2/022 , A61K35/55 , A61K9/0024 , A61K9/0085 , A61M31/002 , A61M37/0069 , A61M39/0208 , B01J13/02 , C12N11/04 , C12N5/0012 , C12N5/0614 , C12N5/0619 , C12N5/0676 , A61K2035/126 , A61M2210/0687 , A61M2210/0693 , C12N2533/30
摘要： Implantable therapy systems are disclosed for the local and controlled delivery of a biologically active factor to the brain, spinal cord and other target regions of a subject suffering from a debilitating condition. The method of the invention involves surgically exposing an insertion site, generally located above a predetermined treatment site (12), in a patient. A cannula (20), having an obturator (30) or dilator (104) positioned therein, is inserted at the insertion site, defining a pathway to the treatment site. In some instances, the cannula can be inserted along the path of a guidewire (102) previously positioned at the treatment site. The cannula (20) is preferably a low friction polymeric material such as polytetrafluoroethylene. The cannula (20) generally has an open proximal end for receiving the obturator (30) or dilator (104), and an open distal end, preferably a tapered end, for delivery of neurologically active factors to the treatment site (12). The obturator (30) is then removed from the cannula (20), and a biocompatible tethered vehicle (40) containing a biologically active material is inserted into the cannula along the passageway. A pusher can be inserted within the cannula, behind the vehicle (40), to position the proximal end of the vehicle at the distal end of the cannula (20b). Once the vehicle (40) is positioned near the distal end of the cannula (20), the cannula is removed from the passageway, followed by the pusher, leaving the vehicle (40) positioned at the treatment site (12).
摘要翻译： 公开了植入式治疗系统，用于将局部和受控制的生物活性因子递送至患有衰弱病症的受试者的脑，脊髓和其他目标区域。 本发明的方法涉及通常在患者体内暴露通常位于预定治疗部位（12）上方的插入部位。 具有定位在其中的闭塞器（30）或扩张器（104）的插管（20）插入插入位置，从而限定到治疗部位的通路。 在一些情况下，套管可以沿着预先位于治疗部位的导丝（102）的路径插入。 插管（20）优选为低摩擦聚合材料，例如聚四氟乙烯。 插管（20）通常具有用于接收封闭器（30）或扩张器（104）的开放近端，以及用于将神经活性因子递送至治疗部位（12）的开口远端，优选地为锥形末端。 然后将塞子（30）从插管（20）中取出，并且将包含生物活性物质的生物相容性系留载体（40）沿通道插入插管中。 推动器可以插入插管内，在车辆（40）后面，以将车辆的近端定位在套管（20b）的远端。 一旦车辆（40）定位在套管（20）的远端附近，则套管从通道中移除，随后是推动器，使车辆（40）位于治疗部位（12）处。
-
公开(公告)号：US06179826B2
公开(公告)日：2001-01-30
申请号：US08741228
申请日：1996-10-29
申请人： Patrick Aebischer , Moses Goddard , John G. Moldauer , Paul J. Mulhauser , Anne M. Rathbun , Paul R. Sanberg , Alfred V. Vasconcellos , Nicholas F. Warner
发明人： Patrick Aebischer , Moses Goddard , John G. Moldauer , Paul J. Mulhauser , Anne M. Rathbun , Paul R. Sanberg , Alfred V. Vasconcellos , Nicholas F. Warner
IPC分类号： A61M3100
CPC分类号： A61K9/0092 , A61F2/022 , A61K9/0024 , A61K9/0085 , A61K35/55 , A61K2035/126 , A61M31/002 , A61M37/0069 , A61M39/0208 , A61M2210/0687 , A61M2210/0693 , B01J13/02 , C12N5/0012 , C12N5/0614 , C12N5/0619 , C12N5/0676 , C12N11/04 , C12N2533/30 , A61M2230/005
摘要： Implantable therapy systems are disclosed for the local and controlled delivery of a biologically active factor to the brain, spinal cord and other target regions of a subject suffering from a dibilatating condition. The method of the invention involves surgically exposing an insertion site, generally located above a predetermined treatment site (12), in a patient. A cannula (20), having an obturator (30) or dilator (104) positioned therein, is inserted at the insertion site, defining a pathway to the treatment site. In some instances, the cannula can be inserted along the path of a guidewire (102) previously positioned at the treatment site. The cannula (20) is preferably a low friction polymeric material such as polytetrafluoroethylene. The cannula (20) generally has an open proximal end for receiving the obturator (30) or dilator (104), and an open distal end, preferably a tapered end, for delivery of neurologically active factors to the treatment site (12). The obturator (30) is then removed from the cannula (20), and a biocompatible tethered vehicle (40) containing a biologically active material is inserted into the cannula along the passageway. A pusher can be inserted within the cannula, behind the vehicle (40), to position the proximal end of the vehicle at the proximal tip of the cannula (20b). Once the vehicle (40) is positioned near the proximal end of the cannula (20), the cannula is removed from the passageway, followed by the pusher, leaving the vehicle (40) positioned at the treatment site (12).
摘要翻译： 公开了植入式治疗系统，用于将局部和受控制的生物活性因子递送至患有二体化病症的受试者的脑，脊髓和其他靶区域。 本发明的方法涉及通常在患者体内暴露通常位于预定治疗部位（12）上方的插入部位。 具有定位在其中的闭塞器（30）或扩张器（104）的插管（20）插入插入位置，从而限定到治疗部位的通路。 在一些情况下，套管可以沿着预先位于治疗部位的导丝（102）的路径插入。 插管（20）优选为低摩擦聚合材料，例如聚四氟乙烯。 插管（20）通常具有用于接收封闭器（30）或扩张器（104）的开放近端，以及用于将神经活性因子递送至治疗部位（12）的开口远端，优选地为锥形末端。 然后将塞子（30）从插管（20）中取出，并且将包含生物活性物质的生物相容性系留载体（40）沿通道插入插管中。 推动器可以插入插管内，在车辆（40）后面，以将车辆的近端定位在套管（20b）的近端处。 一旦车辆（40）定位在套管（20）的近端附近，则套管从通道中移开，随后是推动器，使车辆（40）位于治疗部位（12）处。
-
公开(公告)号：US10130683B1
公开(公告)日：2018-11-20
申请号：US14823637
申请日：2015-08-11
摘要： A combined therapy of human umbilical cord blood cells (hUCB) and G-CSF at the acute stage of TBI was tested as a therapeutic for progressive secondary effects of chronic TBI. Rats were treated with saline carrier, or therapeutic in carrier as follows; G-CSF, hUCB, or hUCB and G-CSF, 7-days after TBI. Eight weeks later, behavioral testing was performed and brains harvested to analyze hippocampal cell loss, neuroinflammatory response, and neurogenesis. Results revealed that the monotherapies partially suppressed neuroinflammation and reduced hippocampal cell loss. However, combined therapy of hUCB and G-CSF robustly dampened neuroinflammation, while enhancing endogenous neurogenesis and reducing hippocampal cell loss. Vigorous and long-lasting recovery of motor function accompanied the combined therapy, which was either moderately or short-lived in the monotherapy conditions. These results suggest that combined treatment rather than monotherapy appears optimal for abrogating histophalogical and motor impairments in chronic TBI.
-
公开(公告)号：USD795156S1
公开(公告)日：2017-08-22
申请号：US29545148
申请日：2015-11-10
申请人： Paul R. Sanberg , Stephen Klasko
设计人： Paul R. Sanberg , Stephen Klasko
-
15.发明授权公开(公告)号：US09044431B2
公开(公告)日：2015-06-02
申请号：US13107391
申请日：2011-05-13
CPC分类号： A61K35/14 , A61K35/30 , A61K38/185 , A61K38/1866
摘要： A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co-cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death. Transplantation of menstrual blood-derived stem cells, either intracerebrally or intravenously, after experimentally induced ischemic stroke in adult rats also significantly reduced behavioral and histological impairments compared to vehicle-infused rats.
摘要翻译： 与移植受体完全匹配的细胞类型似乎是最佳方案，以最小的并发症向大量患者群体开放治疗选择。 已经提出使用自体骨髓或脐带血作为细胞治疗的干细胞的良好来源。 月经血被认为是干细胞的另一个重要来源。 培养的月经血液的测定显示它们在合适的条件培养基下表达胚胎样干细胞表型标记物和神经元表型标记物。 氧葡萄糖剥夺中风模型显示，OGD暴露的原代大鼠神经元，与月经血源干细胞共培养或暴露于来自培养的月经血液的培养基，显示出显着降低的细胞死亡。 在实验性诱导的成年大鼠缺血性卒中后，月经血液或静脉内移植月经血源性干细胞也显着降低与载体输注大鼠相比的行为和组织学损伤。
-
公开(公告)号：US08716216B2
公开(公告)日：2014-05-06
申请号：US12118675
申请日：2008-05-09
CPC分类号： C07K14/4703 , A61K38/00 , Y02A50/471
摘要： A composition of an immunosuppressant protein (HISP) which is achieved by the steps of obtaining supernatant from hNT neuronal cells; exposing the supernatant to preparative polyacrylamide gel; placing the active isoelectric fraction on a Blue Sepharose column to bind albumin; and collecting the free fraction containing the concentrated, isolated HISP. The HISP is anionic, has a molecular weight of 40-100 kDa, an isoelectric point of about 4.8 and is obtained from the supernatant of hNT cells. HISP can suppress proliferation of responder peripheral blood mononuclear cells in allogeneic mixed lymphocyte cultures; HISP can suppress T-cell proliferation and IL-2 production in response to phorbol 12-myristate 13-acetate (PMA), ionomycin and concanavalin-A. HISP does not act through the T-cell receptor-CD3 complex or via altered accessory signal cells.
摘要翻译： 通过从hNT神经元细胞获得上清液的步骤实现的免疫抑制蛋白（HISP）的组合物; 将上清液暴露于制备型聚丙烯酰胺凝胶; 将活性等电点部分置于蓝色琼脂糖凝胶柱上以结合白蛋白; 并收集含有浓缩，分离的HISP的游离级分。 HISP为阴离子型，分子量为40-100kDa，等电点为约4.8，由hNT细胞的上清液得到。 HISP可以抑制同种异体混合淋巴细胞培养物中应答者外周血单核细胞的增殖; HISP可以抑制佛波醇12-肉豆蔻酸酯13-乙酸酯（PMA），离子霉素和伴刀豆素A的T细胞增殖和IL-2产生。 HISP不通过T细胞受体-CD3复合物或通过改变的附属信号细胞起作用。
-
公开(公告)号：US20120148540A1
公开(公告)日：2012-06-14
申请号：US13267346
申请日：2011-10-06
CPC分类号： A61K35/26 , C12N5/0018 , C12N2500/84 , C12N2502/078 , C12N2502/30 , C12N2503/02
摘要： The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential of any human or other animal cell in culture. The subject invention further pertains to a method for proliferating cells in culture by contacting cells with the proliferation factors. The proliferated cells can range in plasticity and can include, for example, blast cells, fertilized ova, non-fertilized gametes, embryonic stem cells, adult stem cells, precursor or progenitor cells, and highly specialized cells. Optionally, the cells can be induced to cease proliferation. The proliferated cells of the subject invention are useful for cell therapy, cell/gene therapy, biological production of molecules, and as in vitro models for research, toxicity testing, and drug development.
摘要翻译： 本发明涉及可用于增加培养物中任何人或动物细胞的增殖潜力的肿瘤细胞系，从而提供永生化或连续的细胞系和培养物。 本发明还涉及增殖因子和含有因子的组合物，其能够增加培养物中任何人或其他动物细胞的增殖潜力。 本发明还涉及通过使细胞与增殖因子接触来增殖培养细胞的方法。 增殖的细胞可以在可塑性范围内，并且可以包括例如胚细胞，受精卵，非受精配子，胚胎干细胞，成体干细胞，前体或祖细胞和高度专门的细胞。 任选地，可诱导细胞停止增殖。 本发明的增殖细胞可用于细胞治疗，细胞/基因治疗，分子的生物制备，以及用于研究，毒性测试和药物开发的体外模型。
-
18.发明申请NOVEL METHOD OF PRENATAL ADMINISTRATION OF MAMMALIAN UMBILICAL CORD STEM CELLS FOR THE INTRAUTERINE TREATMENT OF MAMMALIAN LYSOSOMAL STORAGE DISEASES 有权用于治疗MAMMALIAN LYSOSOMAL存储疾病的MAMMALIAN脐带干细胞的初步施用方法公开(公告)号：US20090016998A1
公开(公告)日：2009-01-15
申请号：US12168608
申请日：2008-07-07
CPC分类号： A61K35/44
摘要： A method of treating a fetus or embryo suspected of having a congenital condition that involves an abnormal or missing protein, the method has the steps of a. providing a plurality of human umbilical cord blood in a form suitable for intravenous administration; a b. administering the human umbilical cord blood cells to a mother carrying a fetus of embryo suspected of having said congenital condition. Such congenital conditions include Sanfilippo's syndrome, Hunter's syndrome, Hurler's syndrome, Tay-Sachs disease, Gaucher's disease, von Gierke's disease, Pompes disease, Cori disease, Andersen disease, McArdle's disease, Hers disease, Tauri's disease or Type IX glycogen storage disease.
摘要翻译： 一种治疗怀疑患有涉及异常或缺失蛋白质的先天性病症的胎儿或胚胎的方法，具有以下步骤：a。 提供适合于静脉内施用形式的多种人脐带血; a b。 对携带怀疑有先天性胚胎的胎儿的母亲施用人脐带血细胞。 这种先天性病症包括Sanfilippo综合征，亨特综合征，赫勒勒综合征，泰萨克病，戈谢病，冯·吉尔克病，庞培病，康利病，安徒生病，麦卡德尔病，赫斯病，牛磺病或1型糖原贮积病。
-
公开(公告)号：US06790441B1
公开(公告)日：2004-09-14
申请号：US09593629
申请日：2000-06-13
IPC分类号： A01N6500
CPC分类号： C12N5/0677 , A61K35/12 , C12N5/0619 , C12N2502/246
摘要： According to the present invention, there is provided a biological chamber system having a biochamber defined by outer walls of Sertoli cells. Also provided is a transplantation facilitator including a biochamber. A method of making biochambers by co-culturing facilitator cells and therapeutic cells and then aggregating the facilitator celes is also provided. Also provided is a method of transplanting cells by incorporating transplant cells into a biochamber and transplanting the biochamber containing the transplant cells.
摘要翻译： 根据本发明，提供了一种具有由Sertoli细胞的外壁限定的生物室的生物室系统。 还提供了包括生物室的移植促进剂。 还提供了通过共培养促进细胞和治疗细胞然后聚集辅助细胞来制备生物体的方法。 还提供了通过将移植细胞并入生物室并移植含有移植细胞的生物室来移植细胞的方法。
-
20.发明授权公开(公告)号：US11007230B1
公开(公告)日：2021-05-18
申请号：US15250239
申请日：2016-08-29
摘要： Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by degeneration of motor neurons in the spinal cord and brain. Increasing evidence shows autoimmune mechanisms likely promote disease progression. Human umbilical cord blood (hUCB) derived plasma is rich in cytokines and growth factors that are required for growth and survival of cells during hematopoiesis. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients.
-
-
-
-
-
-
-
-
-
搜索结果
56 条记录 (耗时 0.066 秒)